Novus Therapeutics (NVUS) EPS Estimated At $-2.70, HubSpot (HUBS) Covered By 19 Bulls

July 17, 2017 - By Kurt Siggers

Analysts expect Novus Therapeutics Inc (NASDAQ:NVUS) to report $-2.70 EPS on August, 3.They anticipate $2.10 EPS change or 350.00% from last quarter’s $-0.6 EPS. About 24,298 shares traded. Novus Therapeutics Inc (NASDAQ:NVUS) has 0.00% since July 17, 2016 and is . It has underperformed by 16.70% the S&P500.

Among 21 analysts covering Hubspot Inc (NYSE:HUBS), 19 have Buy rating, 0 Sell and 2 Hold. Therefore 90% are positive. Hubspot Inc had 32 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was initiated by Stifel Nicolaus on Tuesday, July 19 with “Buy”. The stock of HubSpot Inc (NYSE:HUBS) earned “Neutral” rating by BTIG Research on Thursday, April 14. The rating was initiated by Dougherty & Company on Friday, November 6 with “Strong Buy”. The rating was maintained by Canaccord Genuity on Friday, August 7 with “Buy”. The stock of HubSpot Inc (NYSE:HUBS) has “Buy” rating given on Friday, March 31 by BTIG Research. On Thursday, March 30 the stock rating was maintained by IBC with “Buy”. The stock of HubSpot Inc (NYSE:HUBS) has “Outperform” rating given on Friday, December 2 by Oppenheimer. As per Monday, December 19, the company rating was upgraded by Raymond James. Suntrust Robinson initiated it with “Buy” rating and $81 target in Tuesday, June 27 report. Piper Jaffray initiated the stock with “Overweight” rating in Wednesday, June 1 report. See HubSpot Inc (NYSE:HUBS) latest ratings:

27/06/2017 Broker: Suntrust Robinson Rating: Buy New Target: $81.00 Initiate
27/06/2017 Broker: SunTrust Rating: Buy New Target: $81 Initiates Coverage On
05/05/2017 Broker: IBC Rating: Buy New Target: $78.00 Maintain
05/05/2017 Broker: Cowen & Co Rating: Market Perform Old Target: $53.00 New Target: $63.00 Target Up
05/05/2017 Broker: Stephens Rating: Overweight Old Target: $70.00 New Target: $76.00 Target Up
05/05/2017 Broker: Stifel Nicolaus Rating: Buy Old Target: $64.00 New Target: $75.00 Target Up
13/04/2017 Broker: Guggenheim Rating: Buy Initiates Coverage On
03/04/2017 Broker: BTIG Research Old Rating: Neutral New Rating: Buy New Target: $73.00 Upgrade
31/03/2017 Broker: BTIG Research Old Rating: Neutral New Rating: Buy New Target: $73.00 Upgrade
30/03/2017 Broker: IBC Rating: Buy New Target: $70.00 Maintain

Investors sentiment increased to 1.54 in 2016 Q4. Its up 0.06, from 1.48 in 2016Q3. It improved, as 25 investors sold HubSpot Inc shares while 36 reduced holdings. 36 funds opened positions while 58 raised stakes. 31.59 million shares or 1.29% more from 31.19 million shares in 2016Q3 were reported. Moreover, Victory Cap Mngmt Incorporated has 0% invested in HubSpot Inc (NYSE:HUBS) for 39,450 shares. Jpmorgan Chase & invested in 516,839 shares. Clearbridge Investments Llc holds 0.02% of its portfolio in HubSpot Inc (NYSE:HUBS) for 419,735 shares. Balyasny Asset Management Limited Liability Corp has invested 0.01% in HubSpot Inc (NYSE:HUBS). Fortaleza Asset Mngmt has invested 0.26% in HubSpot Inc (NYSE:HUBS). Assetmark Inc holds 0% or 689 shares. Tiaa Cref Investment Mgmt Limited has 84,555 shares. Swiss Bankshares holds 0% or 37,700 shares. Winslow Evans And Crocker holds 0% or 50 shares. Trexquant Lp invested 0.04% of its portfolio in HubSpot Inc (NYSE:HUBS). Guggenheim Capital Lc has 0% invested in HubSpot Inc (NYSE:HUBS). First Tru Lp has invested 0% of its portfolio in HubSpot Inc (NYSE:HUBS). Morgan Stanley reported 0.01% stake. Citadel Advsrs Llc holds 0% of its portfolio in HubSpot Inc (NYSE:HUBS) for 61,487 shares. Invesco invested 0% of its portfolio in HubSpot Inc (NYSE:HUBS).

About 208,906 shares traded. HubSpot Inc (NYSE:HUBS) has risen 55.26% since July 17, 2016 and is uptrending. It has outperformed by 38.56% the S&P500.

HubSpot, Inc. provides a cloud marketing and sales software platform. The company has market cap of $2.67 billion. The Company’s software platform features integrated applications to help businesses attract visitors to their Websites, convert visitors into leads, close leads into clients and delight clients so that they become promoters of those businesses. It currently has negative earnings. These integrated applications include social media, search engine optimization, blogging, Website content management, marketing automation, e-mail, sales productivity, customer relationship management (CRM), analytics and reporting.

Since February 1, 2017, it had 0 insider purchases, and 23 insider sales for $13.70 million activity. Shares for $16,667 were sold by Kelleher John P.. Madeley Hunter also sold $67,100 worth of HubSpot Inc (NYSE:HUBS) on Tuesday, May 2. 19,681 shares were sold by Kinzer John, worth $1.17 million. SKOK DAVID R also sold $944,581 worth of HubSpot Inc (NYSE:HUBS) on Monday, February 6. Shah Dharmesh had sold 17,600 shares worth $1.09M. Sherman J Donald sold $3.86 million worth of HubSpot Inc (NYSE:HUBS) on Monday, March 20. 25,000 shares valued at $1.62 million were sold by Halligan Brian on Thursday, June 15.

Novus Therapeutics, Inc., formerly Tokai Pharmaceuticals, Inc., is a pharmaceutical company. The company has market cap of $39.53 million. The Firm is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It currently has negative earnings. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: